Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of HRS9531 in adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone
CTR20243947Phase 3Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Nov 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in type 2 diabetes mellitus (T2DM), sponsored by Fujian Shengdi Pharmaceuticals. Started Nov 2024; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20243947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243947.